Management Team
Mingdong Zhou, Ph.D.
Founder, Chief Executive Officer & Chief Scientist
    Dr. Zhou is the founder, CEO and Chief Scientist of Zensun. Dr. Zhou earned his B.S. in biology from Fudan University in 1982 and his Ph.D. in cellular and molecular biology from New York State University in 1992. After he completed postdoctoral research training at the University of California, San Diego in 1996, he moved to Sydney, Australia, where he headed the Cell Signaling Laboratory of the Victor Chang Cardiac Research Institute. He discovered important effects of neuregulins in maintaining cardiomyocyte structure and function, as well as the fact that ErbB2/ErbB3 hetero-dimerization is essential for tumor development. Dr. Zhou has authored more than 30 original research papers in PNAS, JACC, JBC, Circulation Research, and other international journals. He has applied for 174 patents, 61 of which have been granted, including 41 world-wide and 20 patents in China. In 2000, Dr. Zhou returned to China and founded Zensun (Shanghai) Sci. & Tech. Co., Ltd. Zensun focuses on leading-edge research and development of mechanism-based healthcare solutions. The current pipeline includes cardiovascular disease treatment, anti-cancer drugs, and treatments for energy metabolism disorders. The first-in-class drug Neucardin™, which addresses wholly innovative targets and mechanisms, is now in phase III clinical trials and will bring revolutionary innovations in cardiomyocyte therapy. After more than ten years of research and development, Zensun’s product line of innovative drugs and medical instruments with short, medium, or long term horizons for commercialization is ready to begin appearing in the global market, and Zensun will become an integrated company doing research, production, and sales.
Xifu Liu, Ph.D.
Executive Vice President, Global Clinical Trials
    Dr. Liu obtained his Ph.D. degree in 1996 from Institute of Genetics, Chinese Academy of Sciences. Later, he undertook postdoctoral training at the Victor Chang Cardiac Research Institute, Australia. In 2000, he helped to found Zensun (Shanghai) Sci & Tech Co., Ltd., and established the research platform of molecular biology, cytobiology, and animal pharmacodynamics. Dr. Liu has authored many original research papers studying the structure and function of ACE and published in peer-reviewed international journals, such as J Biol. Chem. and Proc. Natl. Acad. Sci (USA). Now Dr. Liu heads Zensun’s global clinical trials.
Zhenggang Jiang, Ph.D.
Executive Vice President, Business Development, Intellectual Property, Legal Affairs, and Strategic Planning
    Dr. Jiang joined Zensun in 2008, where he was Group Leader of R&D, Senior Researcher of IP, and Executive Vice President during the past ten years at Zensun. Now, he is taking responsibility for a wide range of tasks, including business development, intellectual property, legal affairs and strategic planning. Dr. Jiang earned his Ph.D. degree at the Medical School of Fudan University with a major in immunology. He has authored more than 20 research papers in international journals.
Chen Zhuge, CFO
    Chen Zhuge graduated from Peking University in 2001. He has more than 15 years of leadership and finance experience in both private companies and multinational corporations, such as P&G, Roland Berger, and Suntech, etc. He has in-depth knowledge and experience in Finance Management, Investment, M&A, and Strategic Planning.
Xiuhua Zhang
Senior Vice President, Secretary of the Board
    Ms. Zhang has served in Zensun since 2002, where she was responsible for fundamental research, grant applications, and during the past years has been in charge of administration and human resources. She has now taken responsibility as Secretary of the Board and is also in charge of investor relationships. She received her Masters in molecular immunology from East China Normal University.
Cangjing Yang, Ph.D.
Senior Vice President, Industrialization
    Dr. Yang received his Ph.D. degree in Genetics from the School of Life Sciences, Fudan University. With solid experience in hormone signaling transduction pathways and four published SCI papers, Dr. Yang leads the company’s pre-clinical research of oncotherapy drugs and industrialization projects for Zensun’s drugs & medical devices.
Robin Allgren, MD Ph.D.
    Dr. Allgren received her Ph.D. degree from Stanford University and her MBA from Golden Gate University. She has more than 25 years of experience, spanning the biotech, pharmaceutical, medical devices, and diagnostics industries. She successfully executed clinical development activities from preclinical stages through IND filing, NDA filing, and approval. She also has great expertise in pharmacovigilance. She has now taken responsibility as CMO in Zensun USA.
Jacky Wu
Vice President, Sales and Marketing
    Mr. Wu holds his Bachelor’s degree from Shanghai Second Medical University, where he majored in Clinical Medicine. He has 20 years of healthcare industry experience working for multinational companies including Schering-Plough, Abbott, and Baxter. He is now overseeing sales and marketing in Zensun.
Xiangge Bai
Vice President, Legal Affairs
    Vice President, Legal Affairs Mr. Bai has more than 15 years of experience in general corporate matters as well expertise in breadth of compliance and governance. He has previously worked for several renowned pharmaceutical companies in China, including public companies listed in the Chinese or U.S. stock markets. He received his Bachelor’s degree from the Law School of Peking University in 2000. He is now in charge of legal affairs and risk control.
Wenkai Li, Ph.D.,
Vice President, R&D
    Dr. Li graduated from the University of Pennsylvania School of Medicine with a Ph.D. in biochemistry and molecular biophysics. Before joining Zensun, Dr. Li held positions of increasing responsibility in the pharmaceutical industry, including Senior Research Biologist and Associate Principal Scientist in Neurology at Merck Research Laboratories, Boston and West Point, PA and Principal Scientist in Neurodegeneration at GSK R&D, Shanghai. Dr. Li has extensive experience in drug discovery and development including the identification and progression of different modality therapeutic assets up to clinical stage. In his current role, Dr. Li oversees the discovery and development of novel medicines.
Ting Dai
Vice President, Administration, Human Resource and Internal Control
    Ms. Dai obtained her EMBA from Shanghai University of Finance and Economics. She joined Zensun in 2005, with extensive operational and managerial experience in financial planning and analysis, accounting, and treasury. In her current position as vice president, Ms. Dai has responsibility for administration, human resources and internal control.
Yiwen Chen .
Vice President, Business Development
    Dr. Chen received his Ph.D. in biomedical sciences from the University of Macau. With his solid experience in biomedical research, drug quality control and assessment, project management, and eight published papers in Science, Dr. Chen is now focusing on Zensun’s business development and project cooperation. He is also a member of the American Chemical Society (ACS).
Xiaorui Wang, Ph.D.,
Deputy Vice President, Regulatory Affairs and Clinical Development
    Dr. Wang graduated from National University of Singapore with a Ph.D. in biochemistry in 2013. Before joining Zensun, she worked at Singapore Bioimaging Consortium, Agency for Science, Technology, and Research (A*STAR) from 2007 to 2014 as a senior research officer and worked on diabetes and obesity area. Her current role covers regulatory affairs and clinical development.
Clinical Trials Recruiting Participants